Name: ETOMIDATE (AmidateR)
Classification: sedative-hypnotic
  • used as induction agent for intubation as general sedative or in rapid sequence induction
  • rapid onset of action usually within 60 seconds (may be 5-15 seconds) with duration of action of 3-5 minutes (may be up to 14 minutes)
  • no analgesic activity; minimal respiratory or cardiovascular effects
  • special access product
  • 0.3 mg/kg to usual maximum of 20 mg IV
  • may require dose reduction in elderly patients
Administration: IV direct over 30-60 seconds
  • use large proximal arm veins or central line if possible to avoid pain on injection
  • Adverse Effects:
    • injection site pain
    • transient skeletal muscle movements including myoclonus
    • hypo-/hyperventilation, apnea
    • arrhythmias
    • laryngospasm
    • nausea/vomiting
    • prolonged suppression of cortisol and aldosterone synthesis with continuous infusion or repeated dosing
    Monitoring Therapy:
    • ECG, HR
    • BP
    • respiratory rate, SpO2
    CCTC Protocol:
    • Must be administered by MD trained in airway management with patient specific approval from senior resident or CCTC consultant.
    • monitoring sheet must be completed by administering physician and returned to Pharmacy Department.

    Lynne Kelly, Pharmacist, CCTC
    Brenda Morgan, Clinical Nurse Specialist, CCTC
    Last Reviewed: September 17, 2018

    LHSCHealth Professionals

    Last Updated September 17, 2018 | © 2007, LHSC, London Ontario Canada